World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29678
World Ranking
16950
National Ranking
8500

Overview

Angelo Di Leo was affiliated with the Academy for Urban School Leadership in the United States and contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology throughout their career. Their work prominently focused on Oncology, Cancer Research, and Pulmonary and Respiratory Medicine, with further specialization in Molecular Biology and Genetics.

The main topics covered in Angelo Di Leo's research included:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Cancer-related Molecular Pathways
  • Monoclonal and Polyclonal Antibodies Research

Angelo Di Leo published in several reputable venues, with frequent contributions to:

  • Cancer Research (6 publications)
  • Annals of Oncology (5 publications)
  • Cancers (3 publications)
  • The Lancet (2 publications)
  • Clinical Cancer Research (2 publications)

Some of Angelo Di Leo's recent research papers included:

  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative, 2021, Cancer Discovery
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials, 2023, The Lancet
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis, 2020, JNCI Journal of the National Cancer Institute

The scientist collaborated frequently with several other researchers including Meredith M. Regan, Marco Colleoni, Matteo Benelli, Ilenia Migliaccio, and Luca Malorni.

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

    Angelo Di Leo;Henry L. Gomez;Zeba Aziz;Zanete Zvirbule

  • Dissecting the Heterogeneity of Triple-Negative Breast Cancer

    Otto Metzger-Filho;Andrew M Tutt;Evandro Azambuja;Kamal S Saini

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Chromogenic in Situ Hybridization: A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples

    Minna Tanner;David Gancberg;Angelo Di Leo;Denis Larsimont

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Angelo Di Leo;Stephen Johnston;Keun Seok Lee;Eva Ciruelos

  • HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil

    Angelo Di Leo;David Gancberg;Denis Larsimont;Minna Tanner

  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

    Sherene Loi;Anita Giobbie-Hurder;Andrea Gombos;Thomas Bachelot

  • Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement

    S. Guiu;S. Michiels;F. André;J. Cortes

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

    Eun Jung Jung;Eun Jung Jung;Libero Santarpia;Juyeon Kim;Francisco J. Esteva

  • Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Ann H. Partridge;R. Bryan Rumble;Lisa A. Carey;Steven E. Come

  • Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications

    Wederson Marcos Claudino;Alessandro Quattrone;Laura Biganzoli;Marta Pestrin

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Giuseppe Viale
Giuseppe Viale University of Milan
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Richard D. Gelber
Richard D. Gelber Harvard University
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Marco Colleoni
Marco Colleoni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens up a range of related online degree paths and healthcare roles to explore. For those interested in the management side of healthcare, pursuing the best online healthcare administration degree can lead to positions in hospital administration, medical practice management, and policy development.

Registered nurses looking to advance their practice can benefit from specialized adn to fnp bridge programs, enabling them to move efficiently from an associate degree in nursing to a family nurse practitioner role. Nutrition is another rewarding field, and earning an online dietitian degree can open doors in clinical dietetics, sports nutrition, or community health.

For those looking for leadership or executive roles within healthcare systems, consider enrolling in top cahme accredited mha programs to earn a Master of Healthcare Administration. Exploring these online degrees provides greater flexibility and a range of career pathways beyond traditional medical school, helping you find the path that best suits your career aspirations.

Best Scientists Citing Angelo Di Leo

Recently Published Articles